Precipio
PRPO
About: Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Employees: 60
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
58% more capital invested
Capital invested by funds: $644K [Q1] → $1.01M (+$371K) [Q2]
1.44% less ownership
Funds ownership: 7.49% [Q1] → 6.05% (-1.44%) [Q2]
8% less funds holding
Funds holding: 12 [Q1] → 11 (-1) [Q2]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Financial journalist opinion
